1. Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for Primary Antifungal Prophylaxis 
Jose F. Falantes, Cristina Calderón, Francisco J. Márquez-Malaver, Manuela Aguilar-Guisado, Almudena Martín-Peña, María L. Martino, Isabel Montero, Jose González, Rocío Parody, Jose A. Pérez-Simón, Ildefonso Espigado 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 14, Issue 1, Pages (February 2014)
DOI: /j.clml
Copyright © 2014 Elsevier Inc. Terms and Conditions

2. Figure 1 Incidence of Febrile Episodes in Each Course of Azacitidine
Clinical Lymphoma, Myeloma and Leukemia  , 80-86DOI: ( /j.clml )
Copyright © 2014 Elsevier Inc. Terms and Conditions

3. Figure 2
Cumulative Incidence Estimates From Competing Risks Data (Estimates at Different Time Points). (A) Patients Treated With Prior Intensive Chemotherapy vs. Patients Receiving Frontline Azacitidine Therapy; (B) Patients With Absolute Neutrophil Count > 0.5 × 109/L vs. Patients With Absolute Neutrophil Count > 0.5 × 109/L After 3 Courses of Azacitidine Therapy
Clinical Lymphoma, Myeloma and Leukemia  , 80-86DOI: ( /j.clml )
Copyright © 2014 Elsevier Inc. Terms and Conditions